OmicsDI
Toggle navigation
Browse
Submit Data
Databases
API
Advanced
Search
13
Results
Show all
Save search
Copy query
Show results for
Unknown
(13)
Publication Date
Release Date
2025
(2)
2021
(2)
2020
(2)
2014
(2)
2024
(1)
2023
(1)
2022
(1)
2018
(1)
2015
(1)
Previous
page
1 / 2
You're on page
1
page
2
Next
page
Sort
by:
Relevance
Page size
10
Development of a Definition of Postacute Sequelae of SARS-CoV-2 Infection.
Not available
S-EPMC10214179
|
biostudies-literature
Cite
Factors associated with D-dimer levels in HIV-infected individuals.
Not available
S-EPMC3953205
|
biostudies-literature
Cite
Severity of cardiovascular disease outcomes among patients with HIV is related to markers of inflammation and coagulation.
Not available
S-EPMC4309077
|
biostudies-literature
Cite
Efficacy and Safety of NVX-CoV2373 in Adults in the United States and Mexico.
Not available
S-EPMC8693692
|
biostudies-literature
Cite
Aflibercept, bevacizumab, or ranibizumab for diabetic macular edema.
Not available
S-EPMC4422053
|
biostudies-literature
Cite
Plasma Vascular Endothelial Growth Factor Concentrations after Intravitreous Anti-Vascular Endothelial Growth Factor Therapy for Diabetic Macular Edema.
Not available
S-EPMC6568257
|
biostudies-literature
Cite
Mapping the human genetic architecture of COVID-19.
Not available
S-EPMC8674144
|
biostudies-literature
Cite
Health Status Outcomes With Percutaneous Coronary Intervention and Coronary Artery Bypass Grafting in ISCHEMIA.
Not available
S-EPMC12492304
|
biostudies-literature
Cite
Lapses in Care Among Patients Assigned to Ranibizumab for Proliferative Diabetic Retinopathy: A Post Hoc Analysis of a Randomized Clinical Trial.
Not available
S-EPMC8532036
|
biostudies-literature
Cite
Initial Invasive or Conservative Strategy for Stable Coronary Disease.
Not available
S-EPMC7263833
|
biostudies-literature
Cite
Previous
page
1 / 2
You're on page
1
page
2
Next
page
Sort
by:
Relevance
Page size
10
OmicsDI
is part of the ELIXIR infrastructure
OmicsDI is an Elixir interoperability service.
Learn more ›
Tweets